The xT CDx is a sophisticated tumor profiling solution designed to advance precision oncology care for solid malignancies. This assay uses next-generation sequencing to assess alterations in 648 genes, identifying single nucleotide variants, multi-nucleotide variants, and insertions/deletions. It also evaluates microsatellite instability status and serves as a companion diagnostic to explore potential treatment avenues according to specific therapeutic product labeling. Uniquely, xT CDx offers mutation profiling through samplings from both formalin-fixed paraffin-embedded tumor tissues and matched normal samples such as blood or saliva, enhancing diagnostic clarity and treatment direction for patients with solid tumors. The comprehensive report generated includes valuable insights that can inform the personalized treatment path for cancer patients.
